Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
May 03, 2018

Enrollment completed in MD Anderson’s 50 patient EGFR exon 20 mutation cohort for poziotinib in non-small cell lung cancer. Nature Medicine publication reported a confirmed objective response rate of 64 percent in the first 11 patients with EGFR exon 20 mutations treated with poziotinib.

May 03, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 3, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The

May 01, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo

Apr 30, 2018

Shareholder Rights Plan Amended to Eliminate Poison Pill Bylaws Amended to Enable Proxy Access and Majority Voting Dr. Bernice R. Welles Recommended to be Added to Spectrum’s Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2018-- Spectrum Pharmaceuticals, Inc.

Apr 27, 2018

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to

Apr 26, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 26, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

Apr 23, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, “Mechanisms and

Apr 17, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 17, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and

Apr 10, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 10, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that updated poziotinib Phase 2 data in MD

Apr 03, 2018

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 3, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy

Mar 07, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 7, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy
Mar 06, 2018
Poziotinib: following promising interim results, the Company is actively enrolling NSCLC patients with exon 20 insertion mutation in a multi-center study. ROLONTIS ™ (eflapegrastim): ADVANCE study recently met the primary efficacy endpoint; RECOVER study fully enrolled; BLA filing expected in Q4
Feb 27, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 27, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the appointment of William L.
Feb 26, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 26, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with
Feb 15, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 15, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business
Feb 05, 2018
The ADVANCE study met the primary efficacy endpoint of non-inferiority in Duration of Severe Neutropenia between ROLONTIS and pegfilgrastim; adverse event profile was similar between the two treatment arms. RECOVER, the second Phase 3 study, is now fully enrolled.
Jan 23, 2018
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 23, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business
Dec 17, 2017
Joseph W. Turgeon Named President and CEO and Elected to the Board of Directors Thomas J. Riga Named Chief Operating Officer Stuart M. Krassner , ScD, PsyD Named Chairman of the Board HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with
Dec 13, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced two oral presentations of data on FOLOTYN and research progress for the
Dec 04, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Displaying 41 - 60 of 781